211 related articles for article (PubMed ID: 37833906)
41. Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR.
Sandén C; Ageberg M; Petersson J; Lennartsson A; Gullberg U
BMC Cancer; 2013 Sep; 13():440. PubMed ID: 24073922
[TBL] [Abstract][Full Text] [Related]
42. Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.
Ageberg M; Drott K; Olofsson T; Gullberg U; Lindmark A
Genes Chromosomes Cancer; 2008 Apr; 47(4):276-87. PubMed ID: 18181180
[TBL] [Abstract][Full Text] [Related]
43. Imatinib therapy in acute myeloid leukemia with DEK-NUP214 and FIP1L1-PDGFRA rearrangement: A case report.
Yang Y; Lin H; Du Z; Hu R; Tang Y; Liang X; Sun J; Tan Y
Oncol Lett; 2020 May; 19(5):3587-3592. PubMed ID: 32269633
[TBL] [Abstract][Full Text] [Related]
44. Multiparameter analysis of acute mixed lineage leukemia: correlation of a B/myeloid immunophenotype and immunoglobulin and T-cell receptor gene rearrangements with the presence of the Philadelphia chromosome translocation in acute leukemias with myeloid morphology.
Saikevych IA; Kerrigan DP; McConnell TS; Head DR; Appelbaum FR; Willman CL
Leukemia; 1991 May; 5(5):373-82. PubMed ID: 2033959
[TBL] [Abstract][Full Text] [Related]
45. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.
Van Vlierberghe P; van Grotel M; Tchinda J; Lee C; Beverloo HB; van der Spek PJ; Stubbs A; Cools J; Nagata K; Fornerod M; Buijs-Gladdines J; Horstmann M; van Wering ER; Soulier J; Pieters R; Meijerink JP
Blood; 2008 May; 111(9):4668-80. PubMed ID: 18299449
[TBL] [Abstract][Full Text] [Related]
46. SET-CAN/NUP214 fusion gene in leukemia: general features and clinical advances.
Song J; Li H; Fan S
Front Oncol; 2023; 13():1269531. PubMed ID: 37909026
[No Abstract] [Full Text] [Related]
47. Double and single mixed-lineage leukemia-rearranged subclones in pediatric acute myeloid leukemia: a case report.
McGrath M; Smink G
J Med Case Rep; 2021 May; 15(1):228. PubMed ID: 33957966
[TBL] [Abstract][Full Text] [Related]
48. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity.
Inhorn RC; Aster JC; Roach SA; Slapak CA; Soiffer R; Tantravahi R; Stone RM
Blood; 1995 Apr; 85(7):1881-7. PubMed ID: 7661940
[TBL] [Abstract][Full Text] [Related]
49. Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic
Stukaite-Ruibiene E; Norvilas R; Dirse V; Stankeviciene S; Vaitkeviciene GE
Pathol Oncol Res; 2022; 28():1610570. PubMed ID: 36172171
[TBL] [Abstract][Full Text] [Related]
50. Complete Bone Marrow Necrosis with Charcot-Leyden Crystals Caused by Myeloid Neoplasm with Mutated NPM1 and TET2.
Saito K; Sato T; Notohara K; Nannya Y; Ogawa S; Ueda Y
Intern Med; 2022 Nov; 61(21):3265-3269. PubMed ID: 35185048
[TBL] [Abstract][Full Text] [Related]
51. Detection of a cryptic
Peterson JF; Pitel BA; Smoley SA; Smadbeck JB; Johnson SH; Vasmatzis G; Koon SJ; Webley MR; McGrath M; Bayerl MG; Baughn LB; Rowsey RA; Ketterling RP; Greipp PT; Hoppman NL
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30936193
[TBL] [Abstract][Full Text] [Related]
52. Coexistence of Non-Hodgkin's Lymphoma and Acute Myeloid Leukemia at Initial Diagnosis: A Case Report.
Ke MM; Wang ZZ; Wan Q; Chen ZJ
Curr Med Imaging; 2023; 19(10):1219-1223. PubMed ID: 36177617
[TBL] [Abstract][Full Text] [Related]
53. NUP214 in Leukemia: It's More than Transport.
Mendes A; Fahrenkrog B
Cells; 2019 Jan; 8(1):. PubMed ID: 30669574
[TBL] [Abstract][Full Text] [Related]
54. Gene rearrangements in bone marrow cells of patients with acute myelogenous leukemia.
Schmetzer HM; Braun S; Wiesner D; Duell T; Gerhartz HH; Mittermueller J
Acta Haematol; 2000; 103(3):125-34. PubMed ID: 10940650
[TBL] [Abstract][Full Text] [Related]
55. High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias.
Petti MC; Tafuri A; Latagliata R; Aloe Spiriti MA; Montefusco E; Mancini M; Meloni G; Petrucci MT; Spadea A; Redi R; Alimena G; Mandelli F
Ann Hematol; 2003 Aug; 82(8):476-480. PubMed ID: 12835916
[TBL] [Abstract][Full Text] [Related]
56. Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
Campregher PV; Halley NDS; Vieira GA; Fernandes JF; Velloso EDRP; Ali S; Mughal T; Miller V; Mangueira CLP; Odone V; Hamerschlak N
Leuk Lymphoma; 2017 Dec; 58(12):2969-2972. PubMed ID: 28509585
[No Abstract] [Full Text] [Related]
57. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma.
Ahlmann M; Meyer C; Marschalek R; Burkhardt B; Koehler G; Klapper W; Juergens H; Rossig C
Eur J Haematol; 2014 Oct; 93(4):349-53. PubMed ID: 24635731
[TBL] [Abstract][Full Text] [Related]
58. Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion.
Mizoguchi Y; Fujita N; Taki T; Hayashi Y; Hamamoto K
Am J Hematol; 2009 May; 84(5):295-7. PubMed ID: 19338047
[TBL] [Abstract][Full Text] [Related]
59. Diagnosis of rare subtypes of acute myeloid leukaemia and related neoplasms.
George TI; Bajel A
Pathology; 2021 Apr; 53(3):312-327. PubMed ID: 33676766
[TBL] [Abstract][Full Text] [Related]
60. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
